Evidence map›Paper›PMID 33013383›Full record

ArticleFrontiers in pharmacology2020

Formononetin Attenuates Airway Inflammation and Oxidative Stress in Murine Allergic Asthma.

La Yi, Jie Cui, Wenqian Wang, Weifeng Tang, Fangzhou Teng, Xueyi Zhu, Jingjing Qin, Tulake Wuniqiemu, Jing Sun, Ying Wei and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 89 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Heliyon · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

La YiDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Jie CuiDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Wenqian WangDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Weifeng TangDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Fangzhou TengDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Xueyi ZhuDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Jingjing QinDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Tulake WuniqiemuDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Jing SunDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Ying WeiDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Jingcheng DongDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Fudan University · CNHuashan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic asthma has been considered as a respiratory disorder with pathological features of airway inflammation and remodeling, which involves oxidative stress. Formononetin (FMT) is a bioactive isoflavone obtained from Chinese herb Radix Astragali, and has been reported to have notable anti-inflammatory and antioxidant effects in several diseases. The purpose of our study was to elaborate the effects of FMT on asthma and the underlying mechanisms. To establish allergic asthma model, BALB/c mice were given ovalbumin (OVA) sensitization and challenge, treated with FMT (10, 20, 40 mg/kg) or dexamethasone (2 mg/kg). The effects of FMT on lung inflammation and oxidative stress were assessed. In OVA-induced asthmatic mice, FMT treatments significantly ameliorated lung function, alleviated lung inflammation including infiltration of inflammatory cells, the elevated levels of interleukin (IL)-4, IL-5, and IL-13, immunoglobulin (Ig) E, C-C motif chemokine ligand 5 (CCL5, also known as RANTES), CCL11 (also called Eotaxin-1), and IL-17A. In addition, FMT treatments eminently blunted goblet cell hyperplasia and collagen deposition, and remarkably reduced oxidative stress as displayed by decreased reactive oxygen species (ROS), and increased superoxide diamutase (SOD) activity. Furthermore, to clarify the potential mechanisms responsible for the effects, we determined the inflammation and oxidation-related signaling pathway including nuclear factor kappa β (NF-κB), c-Jun N-terminal kinase (JNK), and the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). FMT treatments appeared to dramatically inhibit the activation of NF-κB and JNK, significantly elevated the expression of heme oxygenase 1 (HO-1) but failed to activate expression of Nrf2. In conclusion, our study suggested that FMT had the therapeutic effects in attenuating airway inflammation and oxidative stress in asthma.

Indexed as

airway inflammationasthmac-Jun N-terminal kinaseformononetinnuclear factor erythroid 2-related factor 2nuclear factor kappa βoxidative stress

Identifiers

PMID33013383
PMCPMC7500463
OpenAlexW3083440017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.